| Year |
Citation |
Score |
| 2022 |
Connor MP, Loren AW, Hexner EO, Martin ME, Gill SI, Luger SM, Mangan JK, Perl AE, McCurdy SR, Pratz KW, Timlin C, Freyer CW, Carulli A, Catania C, Smith J, et al. Clofarabine and busulfan myeloablative conditioning in allogeneic hematopoietic cell transplant for patients with active myeloid malignancies. Transplantation and Cellular Therapy. PMID 36336258 DOI: 10.1016/j.jtct.2022.10.027 |
0.366 |
|
| 2022 |
Freyer CW, Carulli A, Gier S, Ganetsky A, Timlin C, Schuster M, Babushok D, Frey NV, Gill SI, Hexner EO, Luger SM, Mangan JK, Martin ME, McCurdy SR, Perl AE, et al. Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide. Leukemia & Lymphoma. 1-9. PMID 35188052 DOI: 10.1080/10428194.2022.2042686 |
0.303 |
|
| 2021 |
Freyer CW, Gier S, Moyer ME, Berryman N, Carulli A, Ganetsky A, Timlin C, Babushok DV, Frey NV, Gill SI, Hexner EO, Loren AW, Mangan JK, Martin ME, McCurdy S, et al. Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay. Transplantation and Cellular Therapy. 27: 431.e1-431.e8. PMID 33965188 DOI: 10.1016/j.jtct.2021.01.028 |
0.317 |
|
| 2020 |
Freyer CW, Carulli A, Ganetsky A, Hughes ME, Krause TM, Timlin C, Frey NV, Gill SI, Hexner EO, Loren AW, Mangan JK, Martin ME, McCurdy SR, Perl AE, Pratz K, et al. Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation. Leukemia & Lymphoma. 1-8. PMID 32482107 DOI: 10.1080/10428194.2020.1765239 |
0.343 |
|
| 2020 |
Kim GYG, Burns J, Freyer CW, Hamilton KW, Frey NV, Gill SI, Hexner EO, Luger SM, Mangan JK, Martin ME, McCurdy SR, Perl AE, Porter DL, Schuster MG, Stadtmauer EA, et al. Risk of Invasive Fungal Infections in Patients with High-Risk MDS and AML Receiving Hypomethylating Agents. American Journal of Hematology. PMID 32242967 DOI: 10.1002/Ajh.25808 |
0.359 |
|
| 2019 |
Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, et al. Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901892. PMID 31815579 DOI: 10.1200/Jco.19.01892 |
0.319 |
|
| 2019 |
Mistry RH, Hexner EO, Mangan JK. Persistent Mixed Donor Chimerism following Double Umbilical Cord Transplantation in a Patient with T-Cell Prolymphocytic Leukemia. Case Reports in Hematology. 2019: 8437805. PMID 31612087 DOI: 10.1155/2019/8437805 |
0.411 |
|
| 2019 |
Mangan JK, Ajmal I, Frey NV, Hexner EO, Loren AW, Carroll M, Luger SM. A Pilot Study of Exjade (Deferasirox) As Monotherapy in Higher Risk MDS or Acute Myeloid Leukemia Blood. 134: 5155-5155. DOI: 10.1182/Blood-2019-131668 |
0.413 |
|
| 2019 |
McCurdy SR, Gier SH, Babushok DV, Frey NV, Gill SI, Hexner EO, Loren AW, Mangan JK, Martin ME, Perl AE, Maillard I, Pratz KW, Porter DL, Carroll MP, Gimotty PA, et al. Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome Blood. 134: 2209-2209. DOI: 10.1182/Blood-2019-124468 |
0.38 |
|
| 2019 |
Freyer C, Ganetsky A, Timlin C, Babushok D, Frey NV, Gill SI, Hexner EO, Loren AW, Mangan J, Martin ME, McCurdy SR, Perl AE, Smith J, Luger SM, Stadtmauer EA, et al. Leucovorin Following Methotrexate Graft-Vs-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment and Length of Hospitalization in Myeloablative Allogeneic Hematopoietic Transplantation Biology of Blood and Marrow Transplantation. 25: S283. DOI: 10.1016/J.Bbmt.2018.12.355 |
0.385 |
|
| 2018 |
Freyer CW, Mangan JK. Dose-related periorbital edema following sorafenib in a patient with acute myeloid leukemia. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 1078155218818719. PMID 30537918 DOI: 10.1177/1078155218818719 |
0.335 |
|
| 2018 |
Reshef R, Ganetsky A, Acosta EP, Blauser R, Crisalli L, McGraw J, Frey NV, Hexner EO, Hoxie JA, Loren AW, Luger SM, Mangan J, Stadtmauer EA, Mick R, Vonderheide RH, et al. Extended CCR5 Blockade for Graft-Versus-Host Disease Prophylaxis Improves Outcomes of Reduced Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 30315941 DOI: 10.1016/J.Bbmt.2018.09.034 |
0.408 |
|
| 2018 |
Ganetsky A, Han JH, Hughes ME, Babushok DV, Frey NV, Gill SI, Hexner EO, Loren AW, Luger SM, Mangan JK, Martin ME, Smith J, Freyer CW, Gilmar C, Schuster M, et al. Oral vancomycin prophylaxis is highly effective in preventing Clostridium difficile infection in allogeneic hematopoietic cell transplant recipients. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 30256954 DOI: 10.1093/Cid/Ciy822 |
0.351 |
|
| 2018 |
Ganetsky A, Frey NV, Hexner EO, Loren AW, Gill SI, Luger SM, Mangan JK, Martin ME, Babushok DV, Drobyski WR, Smith J, Timlin C, Freyer CW, Stadtmauer EA, Porter DL. Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract. Bone Marrow Transplantation. PMID 29795429 DOI: 10.1038/S41409-018-0236-Z |
0.416 |
|
| 2018 |
Kasner MT, Mick R, Jeschke GR, Carabasi M, Filicko-O'Hara J, Flomenberg N, Frey NV, Hexner EO, Luger SM, Loren AW, Mangan JK, Wagner JL, Weiss M, Carroll M, Perl AE. Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition. Investigational New Drugs. PMID 29607465 DOI: 10.1007/S10637-018-0585-X |
0.375 |
|
| 2018 |
Manning BM, Sussman RT, Deihimi S, Frey NV, Hexner EO, Loren AW, Luger S, Mangan JK, Martin ME, McCurdy SR, Morrissette JJ, Perl AE, Stadtmauer EA, Porter DL, Gill SI. Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing Blood. 132: 2134-2134. DOI: 10.1182/Blood-2018-99-117410 |
0.406 |
|
| 2018 |
McMahon CM, Nelson N, Ganetsky A, Mangan JK, Frey NV, Perl AE, Martin ME, McCurdy SR, Loren AW, Hexner EO, Bagg A, Morrissette JJ, Luger S. Limited FISH Testing for MDS-Defining Cytogenetic Abnormalities Rapidly Identifies Patients with Newly Diagnosed AML Eligible for CPX-351 Blood. 132: 4785-4785. DOI: 10.1182/Blood-2018-99-116415 |
0.358 |
|
| 2018 |
Freyer CW, Ganetsky A, Hughes ME, Krause TM, Timlin C, Frey NV, Hexner EO, Loren AW, Mangan JK, Martin ME, McCurdy SR, Perl AE, Porter DL, Luger S. Venous Thromboembolism Following Pegaspargase in Adults Receiving Antithrombin Supplementation: A Single Center Characterization of Risk Factors and an Assessment of Supplementation Practice Blood. 132: 4023-4023. DOI: 10.1182/Blood-2018-99-112604 |
0.397 |
|
| 2018 |
Freyer CW, Ganetsky A, Timlin C, Babushok DV, Frey NV, Gill SI, Hexner EO, Loren AW, Mangan JK, Martin ME, McCurdy SR, Perl AE, Luger S, Smith J, Stadtmauer E, et al. Leucovorin Following Methotrexate Graft-Vs-Host Disease Prophylaxis in Myeloablative Allogeneic Hematopoietic Transplantation Shortens the Duration of Mucositis and Hospitalization Blood. 132: 5696-5696. DOI: 10.1182/Blood-2018-99-111550 |
0.407 |
|
| 2016 |
Hogan JJ, Loren AW, Denker MG, Mangan JK. Edema with hypoalbuminemia as a rare manifestation of chronic graft versus host disease after allogeneic hematopoietic cell transplant. Leukemia & Lymphoma. 1-3. PMID 27998198 DOI: 10.1080/10428194.2016.1270451 |
0.37 |
|
| 2016 |
Yam C, Crisalli L, Luger SM, Loren AW, Hexner EO, Frey NV, Mangan JK, Gao A, Stadtmauer EA, Porter DL, Reshef R. Unrelated donors are associated with improved relapse free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem-cell transplantation. American Journal of Hematology. PMID 27197602 DOI: 10.1002/Ajh.24424 |
0.452 |
|
| 2016 |
Hexner EO, Luger SM, Reshef R, Jeschke GR, Mangan JK, Frey NV, Frank DM, Richman LP, Vonderheide RH, Aqui NA, Rosenbach M, Zhang Y, Chew A, Loren AW, Stadtmauer EA, et al. Infusion of CD3/CD28 co-stimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment. American Journal of Hematology. PMID 26858124 DOI: 10.1002/Ajh.24303 |
0.423 |
|
| 2016 |
Walling CC, Shaw PA, Frey NV, Gill SI, Hexner EO, Loren AW, Luger S, Mangan JK, Martin ME, Smith J, Stadtmauer EA, Porter DL. Allogeneic Stem Cell Transplantation in Patients ≥70 Years Old Blood. 128: 2309-2309. DOI: 10.1182/Blood.V128.22.2309.2309 |
0.429 |
|
| 2016 |
Ganetsky A, Frey NV, Loren AW, Hexner EO, Mangan JK, Gill SI, Luger S, Cohen AD, Babushok DV, Stadtmauer EA, Smith J, Drobyski WR, Kraus SK, Timlin C, Porter DL. Tocilizumab Is Highly Active for Severe Steroid-Refractory Acute Graft-Versus-Host Disease of the Gastrointestinal Tract Blood. 128: 2245-2245. DOI: 10.1182/Blood.V128.22.2245.2245 |
0.423 |
|
| 2016 |
Ganetsky A, Han JH, Hughes ME, Babushok DV, Frey NV, Gill SI, Hexner E, Loren AW, Luger S, Mangan JK, Smith J, Stadtmauer EA, Freyer CW, Gilmar C, Porter DL. Oral Vancomycin Is Highly Effective in Preventing Clostridium Difficile infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients Blood. 128: 2225-2225. DOI: 10.1182/Blood.V128.22.2225.2225 |
0.434 |
|
| 2016 |
Canaani J, Frey NV, Gill S, Luskin MR, Hexner EO, Loren AW, Luger SM, Mangan J, Porter DL, Perl AE. Use of FLT3 Inhibitors to Bridge Relapsed/Refractory AML Patients to an Allogeneic Stem Cell Transplant Biology of Blood and Marrow Transplantation. 22: S199-S200. DOI: 10.1016/J.Bbmt.2015.11.589 |
0.419 |
|
| 2015 |
Reshef R, Huffman AP, Gao A, Luskin MR, Frey NV, Gill SI, Hexner EO, Kambayashi T, Loren AW, Luger SM, Mangan JK, Nasta SD, Richman LP, Sell M, Stadtmauer EA, et al. High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26056179 DOI: 10.1200/Jco.2014.60.1203 |
0.406 |
|
| 2015 |
Orlowski RJ, Mangan JK, Luger SM. Approach to patients with primary refractory acute myeloid leukemia. Current Opinion in Hematology. 22: 97-107. PMID 25575037 DOI: 10.1097/Moh.0000000000000115 |
0.442 |
|
| 2015 |
Bagley SJ, Sehgal AR, Gill S, Frey NV, Hexner EO, Loren AW, Mangan JK, Porter DL, Stadtmauer EA, Reshef R, Luger SM. Acute cholecystitis is a common complication after allogeneic stem cell transplantation and is associated with the use of total parenteral nutrition. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 21: 768-71. PMID 25543093 DOI: 10.1016/J.Bbmt.2014.12.005 |
0.443 |
|
| 2015 |
Parasuraman SV, Naim AB, Paranagama DC, Thyne M, Goldberger S, Mascarenhas JO, Mangan J, Fazal S, Miller CB, Mesa RA. Financial Burden of Myeloproliferative Neoplasms on Patients: Results from the MPN Landmark Survey in the United States Blood. 126: 5561-5561. DOI: 10.1182/Blood.V126.23.5561.5561 |
0.327 |
|
| 2015 |
Fazal S, Miller CB, Mascarenhas JO, Thyne M, Goldberger S, Paranagama DC, Parasuraman SV, Naim AB, Mangan J, Mesa RA. Phlebotomy Frequency and Quality of Life and Productivity in Patients with Polycythemia Vera: Results from the MPN Landmark Survey in the United States Blood. 126: 5184-5184. DOI: 10.1182/Blood.V126.23.5184.5184 |
0.355 |
|
| 2015 |
Yam C, Crisalli L, Luger S, Loren A, Hexner EO, Frey N, Mangan J, Gao A, Stadtmauer EA, Porter D, Reshef R. Unrelated Donors Are Associated with Improved Relapse Free Survival Compared to Related Donors in Patients with Myelodysplastic Syndrome Undergoing Reduced Intensity Conditioned Allogeneic Stem-Cell Transplantation Blood. 126: 4380-4380. DOI: 10.1182/Blood.V126.23.4380.4380 |
0.421 |
|
| 2015 |
Mesa RA, Miller CB, Mascarenhas JO, Thyne M, Goldberger S, Paranagama DC, Parasuraman SV, Fazal S, Naim AB, Mangan J. Hydroxyurea Treatment History and Quality of Life in Patients with Polycythemia Vera: Results from the MPN Landmark Survey in the United States Blood. 126: 4077-4077. DOI: 10.1182/Blood.V126.23.4077.4077 |
0.353 |
|
| 2015 |
Canaani J, Luskin MR, Loren A, Timlin C, Mangan J, Hexner EO, Frey NV, Porter DL, Stadtmauer EA, Luger S. Outcome of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Cytarabine Monotherapy Blood. 126: 2543-2543. DOI: 10.1182/Blood.V126.23.2543.2543 |
0.397 |
|
| 2015 |
Reshef R, Huffman AP, Gao A, Sell M, Luskin MR, Luger S, Loren A, Hexner EO, Nasta SD, Frey NV, Gill S, Mangan J, Richman LP, Kambayashi T, Stadtmauer EA, et al. A Survival Benefit for Reduced Intensity Allogeneic Transplants from Young Unrelated Donors Compared to Older Sibling Donors Depends on the Graft CD8 T-Cell Content Biology of Blood and Marrow Transplantation. 21: S42-S43. DOI: 10.1016/J.Bbmt.2014.11.036 |
0.367 |
|
| 2014 |
Reshef R, Hexner EO, Loren AW, Frey NV, Stadtmauer EA, Luger SM, Mangan JK, Gill SI, Vassilev P, Lafferty KA, Smith J, Van Deerlin VM, Mick R, Porter DL. Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 20: 1758-66. PMID 25016197 DOI: 10.1016/J.Bbmt.2014.07.003 |
0.423 |
|
| 2014 |
Luskin MR, Carroll M, Morrissette JJ, Daber RD, Frey NV, Loren AW, Hexner EO, Mangan JK, Perl AE, Sloan CE, Stadtmauer EA, Bagg A, Luger SM, Porter DL, Reshef R. Next-generation sequencing to identify mutations that may predict outcome after allogeneic stem cell transplantation for AML. Journal of Clinical Oncology. 32: 7043-7043. DOI: 10.1200/Jco.2014.32.15_Suppl.7043 |
0.425 |
|
| 2014 |
Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Dubinski DG, Boyle J, Mascarenhas JO. Gaps in Perception Between Patients and Physicians Regarding Symptomatology and Treatment Attitudes for Myeloproliferative Neoplasms: MPN LANDMARK SURVEY Blood. 124: 4827-4827. DOI: 10.1182/Blood.V124.21.4827.4827 |
0.326 |
|
| 2014 |
Frey NV, Luger S, Mangan J, Zebrowski A, Loren AW, Minderman H, Baird J, Porter DL, Hexner EO, Kumar AJ, Luskin MR, Perl AE, Carroll M. A Phase I Study Using Single Agent Birinapant in Patients with Relapsed Myelodysplastic Syndrome and Acute Myelogenous Leukemia Blood. 124: 3758-3758. DOI: 10.1182/Blood.V124.21.3758.3758 |
0.354 |
|
| 2014 |
Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Dubinski DG, Boyle J, Mascarenhas JO. Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Overall Health and Productivity: Results from the MPN LANDMARK SURVEY in the United States Blood. 124: 3183-3183. DOI: 10.1182/Blood.V124.21.3183.3183 |
0.332 |
|
| 2014 |
Reshef R, Mangan JK, Luger SM, Loren AW, Hexner EO, Frey NV, Stadtmauer EA, Blauser RE, Richman LP, Huffman AP, Ganetsky A, Acosta EP, Hoxie JA, Mick R, Vonderheide RH, et al. Extended CCR5 Blockade in Graft-Versus-Host Disease Prophylaxis – a Phase II Study Blood. 124: 2491-2491. DOI: 10.1182/Blood.V124.21.2491.2491 |
0.453 |
|
| 2014 |
Hsu J, Kumar AJ, Carroll MP, Frey NV, Shah NN, Jianhua Z, Hexner EO, Loren AW, Mangan JK, Perl AE, Porter D, Morrissette J, Luger SM. ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML? Blood. 124: 2343-2343. DOI: 10.1182/Blood.V124.21.2343.2343 |
0.319 |
|
| 2014 |
Reshef R, Huffman AP, Gao A, Sell M, Luskin MR, Luger SM, Loren AW, Hexner EO, Nasta SD, Frey NV, Gill SI, Mangan J, Richman LP, Kambayashi T, Stadtmauer EA, et al. CD8 Cell Dose in Peripheral Blood Stem-Cell Grafts Correlates with Relapse and Survival after Reduced Intensity Allogeneic Stem-Cell Transplantation Blood. 124: 1260-1260. DOI: 10.1182/Blood.V124.21.1260.1260 |
0.36 |
|
| 2014 |
Zebrowski A, Hanlon A, Mangan J, Pinto-Martin J, Luger SM, Loren AW, Hexner EO, Reshef R, Gill SI, Smith J, Stadtmauer EA, Porter D, Frey NV. Clofarabine Busulfan Conditioning Improves Outcomes in Patients with Active Acute Myelogenous Leukemia Undergoing Allogeneic Stem Cell Transplant Blood. 124: 1239-1239. DOI: 10.1182/Blood.V124.21.1239.1239 |
0.409 |
|
| 2013 |
Diab A, Zickl L, Abdel-Wahab O, Jhanwar S, Gulam MA, Panageas KS, Patel JP, Jurcic J, Maslak P, Paietta E, Mangan JK, Carroll M, Fernandez HF, Teruya-Feldstein J, Luger SM, et al. Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. Leukemia Research. 37: 32-6. PMID 23102703 DOI: 10.1016/J.Leukres.2012.08.025 |
0.377 |
|
| 2013 |
Bagley SJ, Sehgal AR, Frey NV, Gill S, Hexner E, Loren AW, Mangan JK, Porter DL, Reshef R, Stadtmauer EA, Luger S. Acute Cholecystitis Occurs More Commonly Than Expected Following Allogeneic Hematopoietic Stem Cell Transplantation and Is Ineffectively Diagnosed Using Abdominal Ultrasound Blood. 122: 2046-2046. DOI: 10.1182/Blood.V122.21.2046.2046 |
0.444 |
|
| 2012 |
Mangan JK, Luger SM. A paraneoplastic syndrome characterized by extremity swelling with associated inflammatory infiltrate heralds aggressive transformation of myelodysplastic syndromes/myeloproliferative neoplasms to acute myeloid leukemia: a case series. Case Reports in Hematology. 2012: 582950. PMID 22928125 DOI: 10.1155/2012/582950 |
0.32 |
|
| 2012 |
Frey NV, Hexner EO, Porter DL, Mangan JK, Loren AW, Hatem J, Bagg A, Perl AE, Tsai DE, DiNardo CD, Heitjian D, Luger SM, Carroll M. A Phase I Clinical Trial Using Eltrombopag in Patients with Acute Myelogenous Leukemia Blood. 120: 3576-3576. DOI: 10.1182/Blood.V120.21.3576.3576 |
0.372 |
|
| 2012 |
Perl AE, Jeschke GR, Smith CC, Mangan JK, Luger SM, Carroll M. Single-Cell Pharmacodynamic Monitoring of Ribosomal Protein S6 Phosphorylation During AC220 Therapy Demonstrates in Vivo FLT3 Inhibition in Circulating Leukemic Blasts and Accurately Detects the Development of AC220 Resistance. Blood. 120: 2453-2453. DOI: 10.1182/Blood.V120.21.2453.2453 |
0.357 |
|
| 2012 |
Kasner M, Weiss M, Flomenberg N, Luger SM, Loren AW, Carabasi M, Wagner JL, Mangan JK, Frey NV, Filicko-O'Hara J, Besa EC, Hexner EO, Porter DL, Gitelson E, Martinez-Outschoorn U, et al. Sirolimus Plus MEC Chemotherapy Has Significant Activity in High Risk AML Patients Especially Those Who Exhibit in Vivo Inhibition of the mTOR Pathway Blood. 120: 143-143. DOI: 10.1182/Blood.V120.21.143.143 |
0.385 |
|
| 2011 |
Mangan JK, Luger SM. Salvage therapy for relapsed or refractory acute myeloid leukemia. Therapeutic Advances in Hematology. 2: 73-82. PMID 23556078 DOI: 10.1177/2040620711402533 |
0.43 |
|
| 2011 |
Mangan JK, Speck NA. RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making. Critical Reviews in Oncogenesis. 16: 77-91. PMID 22150309 DOI: 10.1615/Critrevoncog.V16.I1-2.80 |
0.311 |
|
| 2011 |
Cai X, Gaudet JJ, Mangan JK, Chen MJ, De Obaldia ME, Oo Z, Ernst P, Speck NA. Runx1 loss minimally impacts long-term hematopoietic stem cells. Plos One. 6: e28430. PMID 22145044 DOI: 10.1371/Journal.Pone.0028430 |
0.361 |
|
| 2011 |
Perl AE, Jeschke GR, Smith CC, Mangan JK, Luger SM, Carroll M. Phospho-Specific Flow Cytometry of Fixed Whole Blood Demonstrates In Vivo FLT3 Inhibition in Circulating Leukemic Blasts During AC220 Therapy and Accurately Detects the Development of Therapeutic Resistance, Blood. 118: 3502-3502. DOI: 10.1182/Blood.V118.21.3502.3502 |
0.368 |
|
| 2011 |
Hexner E, Luger SM, Mangan JK, Frey NV, Jeschke GR, Frank D, Reshef R, Loren AW, Goldstein SC, Rosenbach M, Nowaczyk C, Schuster M, Stadtmauer EA, Levine BL, June CH, et al. A Phase 1 Dose Escalation Study of Infusion of Ex Vivo CD3/CD28 Costimulated Umbilical Cord Blood-Derived T Cells in Adults Undergoing Transplantation for Advanced Hematologic Malignancies Blood. 118: 3032-3032. DOI: 10.1182/Blood.V118.21.3032.3032 |
0.419 |
|
| 2006 |
Mangan JK, Tantravahi RV, Rane SG, Reddy EP. Granulocyte colony-stimulating factor-induced upregulation of Jak3 transcription during granulocytic differentiation is mediated by the cooperative action of Sp1 and Stat3. Oncogene. 25: 2489-99. PMID 16518416 DOI: 10.1038/Sj.Onc.1209280 |
0.498 |
|
| 2005 |
Mangan JK, Reddy EP. Activation of the Jak3 pathway and myeloid differentiation. Leukemia & Lymphoma. 46: 21-7. PMID 15621777 DOI: 10.1080/10428190400005320 |
0.526 |
|
| 2004 |
Mangan JK, Rane SG, Kang AD, Amanullah A, Wong BC, Reddy EP. Mechanisms associated with IL-6-induced up-regulation of Jak3 and its role in monocytic differentiation. Blood. 103: 4093-101. PMID 14976041 DOI: 10.1182/Blood-2003-06-2165 |
0.502 |
|
| 2002 |
Rane SG, Mangan JK, Amanullah A, Wong BC, Vora RK, Liebermann DA, Hoffman B, Graña X, Reddy EP. Activation of the Jak3 pathway is associated with granulocytic differentiation of myeloid precursor cells. Blood. 100: 2753-62. PMID 12351382 DOI: 10.1182/Blood.V100.8.2753 |
0.52 |
|
| Show low-probability matches. |